Alaleh Nouri, Executive Vice President at PROCEPT BioRobotics Corp (NASDAQ: PRCT), completed an insider sale and recorded additional equity-related transactions in early March 2026, according to a Form 4 filing with the Securities and Exchange Commission.
On March 6, 2026, Nouri sold 6,892 shares of the companys common stock at a price of $23.7019 per share. The total proceeds from that disposition were approximately $163,353. At the time of this report, PROCEPT BioRobotics stock is trading at $25.25 and the company carries a market capitalization of $1.37 billion.
The SEC filing also shows activity on March 5, 2026. On that date, Nouri acquired 43,811 shares of common stock that were reported with a value of $0. Also on March 5, 2026, Nouri was granted 29,615 stock options with an exercise price of $25.35. Those options vest monthly over a four-year period beginning March 5, 2026.
From a financial performance perspective, the company remains unprofitable on a trailing twelve-month basis, reporting a loss of $1.72 per share. Revenue for the same period increased 37 percent to $308 million. An InvestingPro analysis cited in the filing indicates that PRCT appears undervalued at current market levels. The filing also references the availability of a comprehensive Pro Research Report covering PRCT and more than 1,400 U.S. equities for investors seeking additional detail.
Operational and market updates have been uneven. PROCEPT reported fourth-quarter results that missed expectations and subsequently revised its 2026 guidance. That update has been followed by changes to analyst price targets and ratings, but with divergent conclusions about the companys outlook.
Piper Sandler reduced its price target to $28 while maintaining an Overweight rating. Truist Securities cut its price target to $30 from $47 but kept a Buy rating, citing lower forecasts for 2027. By contrast, TD Cowen reiterated its Buy rating and set a $34 price target, noting confidence in the companys recent commercial adjustments despite a notable fall in the stocks value. Separately, Baird initiated coverage with a Neutral rating and a $30 price target, pointing to the firms progress in commercializing its robotic-assisted therapy in the United States since 2020.
Corporate governance changes were also disclosed. PROCEPT named Daniel Puckett to its board of directors and audit committee. Mr. Puckett is classified as an independent director under SEC and Nasdaq rules, and his term is set to run through the 2027 annual meeting.
The collection of insider activity, updated guidance and varied analyst revisions provides multiple data points for investors assessing PROCEPT BioRobotics. The transactions recorded by Nouri include both a cash sale and equity awards with long-term vesting, reflecting the mixed nature of recent company developments.
Key points
- EVP Alaleh Nouri sold 6,892 shares on March 6, 2026 for roughly $163,353, while also acquiring 43,811 shares with a stated value of $0 on March 5, 2026 and receiving 29,615 options exercisable at $25.35 that vest monthly over four years.
- PROCEPT remains unprofitable with a trailing 12-month loss per share of $1.72, though revenue rose 37 percent to $308 million; InvestingPro analysis cited that PRCT appears undervalued at current levels.
- Recent fourth-quarter results missed expectations, prompting a revision to 2026 guidance and a range of analyst reactions, from lowered price targets with maintained positive ratings to new Neutral coverage.
Risks and uncertainties
- Updated guidance following a fourth-quarter shortfall introduces uncertainty around near-term operational performance and revenue trajectory - relevant to healthcare and medtech investors.
- The company remains unprofitable on a trailing twelve-month basis, which may influence investor appetite and valuation assumptions in the medical device sector.
- Divergent analyst price targets and lowered forecasts for 2027 highlight uncertainty in consensus expectations and potential stock volatility in capital markets.